Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,397 across all filing types
Latest filing 2019-09-18 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINA
Regulatory Filings
2019-09-18 English
AstraZeneca amends collaboration with Ironwood
M&A Activity Classification · 99% confidence The document begins with 'RNS Number : 7649M' and is dated 18 September 2019. It details an amendment to a collaboration agreement between AstraZeneca and Ironwood regarding a drug (Linzess) in China, including financial considerations ($35m non-contingent payments, up to $90m milestones, and royalties). The text concludes with standard boilerplate information about RNS, stating: 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K or IR) or a management discussion (MDA). Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIRS, DIV, CAP, etc.), the appropriate fallback category is Regulatory Filings (RNS). The document length is moderate (under 6,000 characters), but its primary function is dissemination via the RNS service.
2019-09-18 English
IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMP
Regulatory Filings
2019-09-09 English
TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CE
Regulatory Filings
2019-09-04 English
Tagrisso approved in China as a 1st-line treatment
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 1622L' and is dated 04 September 2019. It announces a specific corporate event: the approval of the drug Tagrisso in China by the NMPA. This type of announcement, which disseminates material, non-public information to the market via an official channel (RNS), fits the description of a general regulatory announcement that doesn't fit a more specific category like Earnings Release (ER) or a specific financial filing (10-K, IR). Since it is a formal, time-sensitive announcement distributed through the RNS system, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement category.
2019-09-04 English
TOTAL VOTING RIGHTS
Regulatory Filings
2019-09-03 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.